PPAR gamma in pediatric sepsis and the inflammatory response in obesity

Summary

Principal Investigator: JENNIFER MELISSA KAPLAN
Abstract: DESCRIPTION (provided by applicant): This proposal represents a four-year curriculum and research plan that is designed to provide me with the means to transition to an independent investigator. I am an Assistant Professor in Pediatrics in the Division of Critical Care Medicine at Cincinnati Children's Hospital Medical Center with training in molecular epidemiology and sepsis-related basic science research. This application provides a proposed curriculum in epidemiology and immunology and a description of the proposed research project. Sepsis is a clinical entity that involves a massive systemic inflammatory response and can lead to multiple organ dysfunction and death. Systemic physiologic changes lead to endothelial injury, cellular damage and organ failure. The nuclear receptor, peroxisome proliferator-activated receptor-g (PPARg), is involved in the regulation of the inflammatory response in experimental models of sepsis but little is known about the effects in children. Our preliminary data suggest that PPARg is altered in experimental animal models and in critically ill children with sepsis. Furthermore we have demonstrated that diet is also an important factor of sepsis susceptibility in animal models. The central hypothesis of the application is that the PPARg pathway is altered in patients with sepsis and that diet further affects the inflammatory response to sepsis in a PPARg-dependent manner. This hypothesis will be tested by pursuing three specific aims: 1) Determine the alterations in the PPARg pathway in monocytes from children with sepsis;2) Determine the therapeutic efficacy of PPARg ligands in the inflammatory response in ex vivo monocytes from children with septic shock;3) Determine the role of PPARg in the increased susceptibility to sepsis in obesity. Under aim 1 we will utilize a clinical approach to investigate alterations in PPARg in peripheral blood monocytes from children with sepsis. Aim 2 will use a translational approach using ex vivo monocytes to investigate the therapeutic efficacy of PPARg ligands in altering the inflammatory response in sepsis. Aim 3 will use a basic science approach where in vivo and in vitro studies will be used to determine the role of PPARg in the increased susceptibility to sepsis in obesity. The proposed research is significant because it can lead to novel therapies for patients with sepsis, including the potential use of FDA-approved PPARg ligands, thiazolidinediones, which can augment the PPARg pathway.
Funding Period: 2010-06-01 - 2014-05-31
more information: NIH RePORT

Top Publications

  1. pmc Phosphorylation of extracellular signal-regulated kinase (ERK)-1/2 Is associated with the downregulation of peroxisome proliferator-activated receptor (PPAR)-γ during polymicrobial sepsis
    Jennifer M Kaplan
    Division of Critical Care Medicine, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
    Mol Med 16:491-7. 2010
  2. pmc Optimal study design for pioglitazone in septic pediatric patients
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, OH, USA
    J Pharmacokinet Pharmacodyn 38:433-47. 2011
  3. pmc Short-term high fat feeding increases organ injury and mortality after polymicrobial sepsis
    Jennifer M Kaplan
    Division of Critical Care Medicine, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Obesity (Silver Spring) 20:1995-2002. 2012

Detail Information

Publications4

  1. pmc Phosphorylation of extracellular signal-regulated kinase (ERK)-1/2 Is associated with the downregulation of peroxisome proliferator-activated receptor (PPAR)-γ during polymicrobial sepsis
    Jennifer M Kaplan
    Division of Critical Care Medicine, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
    Mol Med 16:491-7. 2010
    ..The inflammatory effects of sepsis cause changes in PPARγ expression and activation, in part, because of phosphorylation of PPARγ by ERK1/2. This phosphorylation can be reversed by ERK1/2 inhibition, thereby improving lung injury...
  2. pmc Optimal study design for pioglitazone in septic pediatric patients
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, OH, USA
    J Pharmacokinet Pharmacodyn 38:433-47. 2011
    ..The pharmacokinetics of pioglitazone were described adequately and simulated data estimates were comparable to literature values. The optimal design provided clinically attainable sample times and windows...
  3. pmc Short-term high fat feeding increases organ injury and mortality after polymicrobial sepsis
    Jennifer M Kaplan
    Division of Critical Care Medicine, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Obesity (Silver Spring) 20:1995-2002. 2012
    ..CD-fed mice. Short duration high fat feeding increases mortality and organ injury following polymicrobial sepsis. These effects correspond to changes in NF-κB...

Research Grants30

  1. LIPID AND LIPOPROTEIN METABOLISM IN ATHEROSCLEROSIS
    Alan M Fogelman; Fiscal Year: 2013
    ..These six Projects will be supported by four cores and together will form a highly interactive and synergistic Program Project that is focused on lipid and lipoprotein metabolism in atherosclerosis. ..
  2. Coordinating Center of Excellence in Social Promotion of Health Equity Research
    GLORIA S MCCUTCHEON; Fiscal Year: 2013
    ..abstract_text> ..
  3. Functional Annotation of the Pancreatic Cancer Genome
    Steven D Leach; Fiscal Year: 2013
    ..Together, these studies will dramatically accelerate the functional annotation of the pancreatic cancer genome, setting the stage for future therapeutic applications. ..
  4. Rocky Mountain Regional Center of Excellence or Biodefense and Emerging Infectiou
    John T Belisle; Fiscal Year: 2013
    ..abstract_text> ..
  5. Improving Cardiac Function After Myocardial Infarction
    Steven R Houser; Fiscal Year: 2013
    ..A gene vector core will generate AAV6 vectors with novel therapeutics for testing in the pig Ml model. An administrative core will ensure data sharing and effective use of all resources. ..
  6. Gene Networks controlling macrophage-adipocyte interactions in insulin
    Christopher K Glass; Fiscal Year: 2013
    ..abstract_text> ..